AbbVie Inc. took a big dive into the increasingly popular antibody-drug conjugate space on 30 November with a $10.1bn buyout offer for ImmunoGen, Inc. and its ovarian cancer ADC Elahere. It also took an attractive takeover option off the board in a field where the Chicago-area big pharma has long wanted to build a significant presence.
AbbVie Spends $10bn On ImmunoGen To Improve Chances In ADC Space
Despite writing down $4bn after the failure of Stemcentrx’s Rova-T, AbbVie will bet big again on the cancer antibody-drug conjugate space by paying a high premium for ImmunoGen, including Elahere and its R&D potential.
More from Deals
More from Business
• By
Stakeholders are pleading for newly confirmed FDA Commissioner Martin Makary to stand up for the agency's high scientific standards and staff as he begins his term.
• By
Plus deals involving Relmada/Trigone, Alvotech/Xbrane, OPKO Health/Entera, iOncologi/TargImmune and more.
• By
With its exon 53-skipping candidate already showing promise in 24-week data, Wave now has 48-week data showing improvements in muscle health and functional outcomes.